TESTBANK
,
,TEST BANK FOR
, ,
Pharmacologyandthe Nursing Process 8thEdition , , , , , ,
LindaLaneLilley,ShellyRainforthCollins,JulieS.Snyder
, , , , , , , ,
Contents
Chapter01: TheNursingProcess andDrugTherapy .......................................................................................... 4
, , , , , , ,
Chapter02:PharmacologicPrinciples ............................................................................................................. 8
, , ,
Chapter03: LifespanConsiderations ............................................................................................................. 14
, , ,
Chapter04: Cultural,Legal,and Ethical Considerations .................................................................................. 20
, , , , , ,
Chapter05:MedicationErrors:Preventing andResponding .......................................................................... 26
, , , , , ,
Chapter06:PatientEducation andDrugTherapy ........................................................................................... 29
, , , , , ,
Chapter07: Over-the-CounterDrugs andHerbalandDietarySupplements .................................................... 34
, , , , , , , ,
Chapter08: GeneTherapyand Pharmacogenomics ....................................................................................... 38
, , , , ,
Chapter09:Photo AtlasofDrug Administration ............................................................................................. 41
, , , , , ,
Chapter10: AnalgesicDrugs .......................................................................................................................... 50
, , ,
Chapter11: Generaland Local Anesthetics .................................................................................................... 57
, , , , ,
Chapter12: CentralNervous SystemDepressants andMuscleRelaxants ........................................................ 61
, , , , , , , ,
Chapter13: CentralNervous System Stimulants andRelated Drugs ............................................................... 66
, , , , , , , ,
Chapter14: AntiepilepticDrugs .................................................................................................................... 70
, , ,
Chapter15:AntiparkinsonDrugs................................................................................................................... 76
, , ,
Chapter16:PsychotherapeuticDrugs ........................................................................................................... 81
, , ,
Chapter17: Substance Abuse ........................................................................................................................ 88
, , ,
Chapter18: AdrenergicDrugs ....................................................................................................................... 93
, , ,
Chapter19:Adrenergic-BlockingDrugs......................................................................................................... 98
, , ,
Chapter20: CholinergicDrugs ..................................................................................................................... 103
, , ,
Chapter21:Cholinergic-BlockingDrugs ...................................................................................................... 108
, , ,
Chapter22:AntihypertensiveDrugs ........................................................................................................... 113
, , ,
Chapter23: AntianginalDrugs..................................................................................................................... 119
, , ,
Chapter24: HeartFailureDrugs................................................................................................................... 125
, , , ,
Chapter25:AntidysrhythmicDrugs ............................................................................................................ 131
, , ,
Chapter26: CoagulationModifierDrugs...................................................................................................... 137
, , , ,
Chapter27: AntilipemicDrugs..................................................................................................................... 143
, , ,
,Chapter28:DiureticDrugs .......................................................................................................................... 148
, , ,
Chapter29: Fluids andElectrolytes .............................................................................................................. 154
, , , ,
Chapter30:PituitaryDrugs ......................................................................................................................... 160
, , ,
Chapter31: Thyroidand AntithyroidDrugs .................................................................................................. 163
, , , , ,
Chapter32:AntidiabeticDrugs.................................................................................................................... 168
, , ,
Chapter33: AdrenalDrugs .......................................................................................................................... 177
, , ,
Chapter34:Women’sHealth Drugs ............................................................................................................. 181
, , , ,
Chapter35:Men’s HealthDrugs .................................................................................................................. 188
, , , ,
Chapter36:Antihistamines,Decongestants,Antitussives,andExpectorants............................................... 193
, , , , , ,
Chapter37:RespiratoryDrugs .................................................................................................................... 198
, , ,
Chapter38: AntibioticsPart 1 ...................................................................................................................... 204
, , , ,
Chapter39: AntibioticsPart 2 ...................................................................................................................... 211
, , , ,
Chapter40:AntiviralDrugs .......................................................................................................................... 216
, , ,
Chapter41:AntitubercularDrugs................................................................................................................ 221
, , ,
Chapter42: AntifungalDrugs ...................................................................................................................... 226
, , ,
Chapter43: Antimalarial,Antiprotozoal,andAnthelminticDrugs ................................................................ 231
, , , , , ,
Chapter44: Anti-inflammatoryandAntigoutDrugs ..................................................................................... 236
, , , , ,
Chapter45: AntineoplasticDrugsPart1:CancerOverview andCellCycle–SpecificDrugs............................... 242
, , , , , , , , , , ,
Chapter46:AntineoplasticDrugs Part2: CellCycle–NonspecificDrugsandMiscellaneousDrugs .................. 248
, , , , , , , , , , ,
Chapter47:BiologicResponse–ModifyingandAntirheumaticDrugs ........................................................... 253
, , , , , ,
Chapter48:ImmunosuppressantDrugs ...................................................................................................... 258
, , ,
Chapter49: ImmunizingDrugs .................................................................................................................... 263
, , ,
Chapter50:Acid-ControllingDrugs ............................................................................................................. 268
, , ,
Chapter51: BowelDisorderDrugs ............................................................................................................... 274
, , , ,
Chapter52: AntiemeticandAntinausea Drugs............................................................................................. 281
, , , , ,
Chapter53: VitaminsandMinerals .............................................................................................................. 286
, , , ,
Chapter54: AnemiaDrugs ........................................................................................................................... 292
, , ,
Chapter55: Nutritional Supplements.......................................................................................................... 299
, , ,
Chapter56:DermatologicDrugs ................................................................................................................. 304
, , ,
Chapter57:OphthalmicDrugs..................................................................................................................... 310
, , ,
Chapter58:OticDrugs................................................................................................................................. 315
, , ,
, Chapter01:TheNursingProcessandDrugTherapy , , , , , , ,
MULTIPLECHOICE ,
1. The nurse is writing a nursing diagnosis for a plan of care for a patient who has been newly
, , , , , , , , , , , , , , , , , ,
diagnosed with type 2 diabetes. Which statement reflects the correct format for a nursing
, , , , , , , , , , , , , ,
diagnosis?
,
a. Anxiety
b. Anxietyrelated to new drug therapy , , , , ,
c. Anxietyrelated to anxious feelings about drugtherapy, as evidenced bystatements such , , , , , , , , , , , ,
as “I’m upset about having to test my blood sugars.”
, , , , , , , , , ,
d. Anxietyrelated to new drugtherapy, as evidenced bystatements such as “I’m upset , , , , , , , , , , , , ,
about having to test my blood sugars.”
, , , , , , ,
ANS: D ,
Formulation of nursing diagnoses is usually a three-step process. “Anxiety” is missing the “related to” , , , , , , , , , , , , , ,
and “as evidenced by” portions of defining characteristics. “Anxiety related to new drugtherapy” is
, , , , , , , , , , , , , , ,
missingthe “asevidenced by”portion ofdefining characteristics. Thestatement beginning “Anxiety
, , , , , , , , , , , , ,
related to anxious feelings” is incorrect because the “related to” section is simply a restatement of the
, , , , , , , , , , , , , , , , ,
problem “anxiety,” not a separate factor related to the response.
, , , , , , , , , ,
DIF: COGNITIVE LEVEL: Understanding (Comprehension) REF:p.7 , , , , ,
TOP: NURSING PROCESS: Nursing Diagnosis
, , , , ,
MSC: NCLEX: SafeandEffective CareEnvironment:Management of Care
, , , , , , , , ,
2. Thepatient is to receive oral guaifenesin (Mucinex) twice aday. Today, the nursewas busyand gave
, , , , , , , , , , , , , , , , ,
the medication 2 hours after the scheduled dose was due. What type of problem does this represent?
, , , , , , , , , , , , , , , , ,
a. “Right time” ,
b. “Rightdose” ,
c. “Right route” ,
d. “Rightmedication” ,
ANS: A ,
“Right time” is correct because the medication was given more than 30 minutes after the scheduled
, , , , , , , , , , , , , , ,
dose was due. “Dose” is incorrect because the dose is not related to the time the medication
, , , , , , , , , , , , , , , , ,
administration is scheduled.“Route”is incorrectbecausetherouteis not affected. “Medication” is
, , , , , , , , , , , , , ,
incorrect because the medication ordered will not change.
, , , , , , , ,
DIF: COGNITIVE LEVEL: Applying (Application) REF:p.11 , , , , ,
TOP: NURSING PROCESS: Implementation
, , , ,
MSC: NCLEX: SafeandEffective Care Environment:Safetyand InfectionControl
, , , , , , , , , ,
3. Thenursehas been monitoringthe patient’s progress on anewdrug regimen since the first dose and
, , , , , , , , , , , , , , , , ,
documenting the patient’s therapeutic response to the medication. Which phase of the nursing
, , , , , , , , , , , , ,
process do these actions illustrate?
, , , , ,
a. Nursingdiagnosis ,
,
,TEST BANK FOR
, ,
Pharmacologyandthe Nursing Process 8thEdition , , , , , ,
LindaLaneLilley,ShellyRainforthCollins,JulieS.Snyder
, , , , , , , ,
Contents
Chapter01: TheNursingProcess andDrugTherapy .......................................................................................... 4
, , , , , , ,
Chapter02:PharmacologicPrinciples ............................................................................................................. 8
, , ,
Chapter03: LifespanConsiderations ............................................................................................................. 14
, , ,
Chapter04: Cultural,Legal,and Ethical Considerations .................................................................................. 20
, , , , , ,
Chapter05:MedicationErrors:Preventing andResponding .......................................................................... 26
, , , , , ,
Chapter06:PatientEducation andDrugTherapy ........................................................................................... 29
, , , , , ,
Chapter07: Over-the-CounterDrugs andHerbalandDietarySupplements .................................................... 34
, , , , , , , ,
Chapter08: GeneTherapyand Pharmacogenomics ....................................................................................... 38
, , , , ,
Chapter09:Photo AtlasofDrug Administration ............................................................................................. 41
, , , , , ,
Chapter10: AnalgesicDrugs .......................................................................................................................... 50
, , ,
Chapter11: Generaland Local Anesthetics .................................................................................................... 57
, , , , ,
Chapter12: CentralNervous SystemDepressants andMuscleRelaxants ........................................................ 61
, , , , , , , ,
Chapter13: CentralNervous System Stimulants andRelated Drugs ............................................................... 66
, , , , , , , ,
Chapter14: AntiepilepticDrugs .................................................................................................................... 70
, , ,
Chapter15:AntiparkinsonDrugs................................................................................................................... 76
, , ,
Chapter16:PsychotherapeuticDrugs ........................................................................................................... 81
, , ,
Chapter17: Substance Abuse ........................................................................................................................ 88
, , ,
Chapter18: AdrenergicDrugs ....................................................................................................................... 93
, , ,
Chapter19:Adrenergic-BlockingDrugs......................................................................................................... 98
, , ,
Chapter20: CholinergicDrugs ..................................................................................................................... 103
, , ,
Chapter21:Cholinergic-BlockingDrugs ...................................................................................................... 108
, , ,
Chapter22:AntihypertensiveDrugs ........................................................................................................... 113
, , ,
Chapter23: AntianginalDrugs..................................................................................................................... 119
, , ,
Chapter24: HeartFailureDrugs................................................................................................................... 125
, , , ,
Chapter25:AntidysrhythmicDrugs ............................................................................................................ 131
, , ,
Chapter26: CoagulationModifierDrugs...................................................................................................... 137
, , , ,
Chapter27: AntilipemicDrugs..................................................................................................................... 143
, , ,
,Chapter28:DiureticDrugs .......................................................................................................................... 148
, , ,
Chapter29: Fluids andElectrolytes .............................................................................................................. 154
, , , ,
Chapter30:PituitaryDrugs ......................................................................................................................... 160
, , ,
Chapter31: Thyroidand AntithyroidDrugs .................................................................................................. 163
, , , , ,
Chapter32:AntidiabeticDrugs.................................................................................................................... 168
, , ,
Chapter33: AdrenalDrugs .......................................................................................................................... 177
, , ,
Chapter34:Women’sHealth Drugs ............................................................................................................. 181
, , , ,
Chapter35:Men’s HealthDrugs .................................................................................................................. 188
, , , ,
Chapter36:Antihistamines,Decongestants,Antitussives,andExpectorants............................................... 193
, , , , , ,
Chapter37:RespiratoryDrugs .................................................................................................................... 198
, , ,
Chapter38: AntibioticsPart 1 ...................................................................................................................... 204
, , , ,
Chapter39: AntibioticsPart 2 ...................................................................................................................... 211
, , , ,
Chapter40:AntiviralDrugs .......................................................................................................................... 216
, , ,
Chapter41:AntitubercularDrugs................................................................................................................ 221
, , ,
Chapter42: AntifungalDrugs ...................................................................................................................... 226
, , ,
Chapter43: Antimalarial,Antiprotozoal,andAnthelminticDrugs ................................................................ 231
, , , , , ,
Chapter44: Anti-inflammatoryandAntigoutDrugs ..................................................................................... 236
, , , , ,
Chapter45: AntineoplasticDrugsPart1:CancerOverview andCellCycle–SpecificDrugs............................... 242
, , , , , , , , , , ,
Chapter46:AntineoplasticDrugs Part2: CellCycle–NonspecificDrugsandMiscellaneousDrugs .................. 248
, , , , , , , , , , ,
Chapter47:BiologicResponse–ModifyingandAntirheumaticDrugs ........................................................... 253
, , , , , ,
Chapter48:ImmunosuppressantDrugs ...................................................................................................... 258
, , ,
Chapter49: ImmunizingDrugs .................................................................................................................... 263
, , ,
Chapter50:Acid-ControllingDrugs ............................................................................................................. 268
, , ,
Chapter51: BowelDisorderDrugs ............................................................................................................... 274
, , , ,
Chapter52: AntiemeticandAntinausea Drugs............................................................................................. 281
, , , , ,
Chapter53: VitaminsandMinerals .............................................................................................................. 286
, , , ,
Chapter54: AnemiaDrugs ........................................................................................................................... 292
, , ,
Chapter55: Nutritional Supplements.......................................................................................................... 299
, , ,
Chapter56:DermatologicDrugs ................................................................................................................. 304
, , ,
Chapter57:OphthalmicDrugs..................................................................................................................... 310
, , ,
Chapter58:OticDrugs................................................................................................................................. 315
, , ,
, Chapter01:TheNursingProcessandDrugTherapy , , , , , , ,
MULTIPLECHOICE ,
1. The nurse is writing a nursing diagnosis for a plan of care for a patient who has been newly
, , , , , , , , , , , , , , , , , ,
diagnosed with type 2 diabetes. Which statement reflects the correct format for a nursing
, , , , , , , , , , , , , ,
diagnosis?
,
a. Anxiety
b. Anxietyrelated to new drug therapy , , , , ,
c. Anxietyrelated to anxious feelings about drugtherapy, as evidenced bystatements such , , , , , , , , , , , ,
as “I’m upset about having to test my blood sugars.”
, , , , , , , , , ,
d. Anxietyrelated to new drugtherapy, as evidenced bystatements such as “I’m upset , , , , , , , , , , , , ,
about having to test my blood sugars.”
, , , , , , ,
ANS: D ,
Formulation of nursing diagnoses is usually a three-step process. “Anxiety” is missing the “related to” , , , , , , , , , , , , , ,
and “as evidenced by” portions of defining characteristics. “Anxiety related to new drugtherapy” is
, , , , , , , , , , , , , , ,
missingthe “asevidenced by”portion ofdefining characteristics. Thestatement beginning “Anxiety
, , , , , , , , , , , , ,
related to anxious feelings” is incorrect because the “related to” section is simply a restatement of the
, , , , , , , , , , , , , , , , ,
problem “anxiety,” not a separate factor related to the response.
, , , , , , , , , ,
DIF: COGNITIVE LEVEL: Understanding (Comprehension) REF:p.7 , , , , ,
TOP: NURSING PROCESS: Nursing Diagnosis
, , , , ,
MSC: NCLEX: SafeandEffective CareEnvironment:Management of Care
, , , , , , , , ,
2. Thepatient is to receive oral guaifenesin (Mucinex) twice aday. Today, the nursewas busyand gave
, , , , , , , , , , , , , , , , ,
the medication 2 hours after the scheduled dose was due. What type of problem does this represent?
, , , , , , , , , , , , , , , , ,
a. “Right time” ,
b. “Rightdose” ,
c. “Right route” ,
d. “Rightmedication” ,
ANS: A ,
“Right time” is correct because the medication was given more than 30 minutes after the scheduled
, , , , , , , , , , , , , , ,
dose was due. “Dose” is incorrect because the dose is not related to the time the medication
, , , , , , , , , , , , , , , , ,
administration is scheduled.“Route”is incorrectbecausetherouteis not affected. “Medication” is
, , , , , , , , , , , , , ,
incorrect because the medication ordered will not change.
, , , , , , , ,
DIF: COGNITIVE LEVEL: Applying (Application) REF:p.11 , , , , ,
TOP: NURSING PROCESS: Implementation
, , , ,
MSC: NCLEX: SafeandEffective Care Environment:Safetyand InfectionControl
, , , , , , , , , ,
3. Thenursehas been monitoringthe patient’s progress on anewdrug regimen since the first dose and
, , , , , , , , , , , , , , , , ,
documenting the patient’s therapeutic response to the medication. Which phase of the nursing
, , , , , , , , , , , , ,
process do these actions illustrate?
, , , , ,
a. Nursingdiagnosis ,
